newsfilter
← Latest News
GlobeNewswire·

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

-- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- -- First patient dosed in ELEVATE-45-201 and the Company is on track to report data from the first patient cohort in mid-2026 --